Clicky

DermTech, Inc.(DMTK)

Description: DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.


Keywords: Medicine Cancer Melanoma Dermatology Diagnostic Tests Pathology Gene Expression Biopsy Risk Assessment Skin Cancer Cutaneous Conditions Assessment Products Melanocytic Nevus Pigmented Lesion Melanoma Skin Cancer Diagnosis Skin Cancer Nevus Non Melanoma Skin Cancer Th17 Inflammatory Pathways

Home Page: www.dermtech.com

DMTK Technical Analysis

11099 North Torrey Pines Road
La Jolla, CA 92037
United States
Phone: 858 450 4222


Officers

Name Title
Dr. John D. Dobak M.D. Pres, CEO & Director
Mr. Kevin Sun M.B.A. CFO, Treasurer & Sec.
Ms. Claudia Ibarra Chief Operating Officer
Mr. Ray Akhavan J.D. Gen. Counsel
Mr. Todd Michael Wood Chief Commercial Officer
Mr. William W. Zondler Chief Information Officer
Mr. Steve E. Kunszabo Sr. Director of Investor Relations
Ms. Jennifer Eilemberg Chief Compliance Officer
Mr. Ray Bassi VP of Sales
Dr. Burkhard Jansen M.D. Chief Medical Affairs Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4347
Price-to-Sales TTM: 4.3608
IPO Date: 2017-08-10
Fiscal Year End: December
Full Time Employees: 255
Back to stocks